Insmed Inc (INSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.96B
Last updated: Nov 17, 2026 at 4:41 PM ET
Insmed Inc (INSM) Statistics
Insmed (INSM) has a market cap of $26.96B and an enterprise value of $27.12B. Revenue grew 239.97% over the last 12 months from the 12 months before. It kept -39.85% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 0.59% above the market cap, as debt exceeds cash.
| Market Cap | $26.96B |
|---|---|
| Enterprise Value | $27.12B |
| Latest price (Nov 17, 2026) | $121.86 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 17.5x and 36.7x. Its year-end P/S ranged from 10.0x to 102.8x from 2018 to 2025.
| P/S Ratio | 17.5x |
|---|---|
| Forward P/S | 14.5x |
| P/B Ratio | 36.7x |
| P/TBV Ratio | 59.0x |
Price Statistics
The stock is down 36.93% over 52 weeks and trades 10.09% above its 50-day average.
| Beta (1Y) | 0.55 |
|---|---|
| 52-Week Change | -36.93% |
| 1-Month Change | +27.88% |
| 3-Month Change | -6.74% |
| 6-Month Change | +13.45% |
| 5-Year Change | +273.40% |
| 10-Year Change | +767.33% |
| Total Return (1Y) | -36.93% |
| Total Return (3Y CAGR) | +69.94% |
| Total Return (5Y CAGR) | +31.85% |
| Return vs SPY (1Y) | -51.12% |
| Max Drawdown (1Y) | -56.54% |
| Max Drawdown (3Y) | -56.54% |
| Sharpe Ratio (1Y) | -0.82 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $110.69 |
| 200-Day Average | $122.83 |
| 52-Week Range | $90.39 to $212.75 |
| RSI (14 Days) | 64.7 |
| Average Volume (20 Days) | 3.74M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.86x current liabilities, and total debt is 0.76x shareholder equity.
| Current Ratio | 2.86x |
|---|---|
| Quick Ratio | 2.59x |
| Debt / Equity | 0.76x |
| Interest Coverage | -6.96x |
Returns and Efficiency
Return on invested capital is -44.18% over the last 12 months, against a 5-year average of -97.55%.
| Return on Equity (ROE) | -83.39% |
|---|---|
| Return on Assets (ROA) | -27.21% |
| Return on Invested Capital (ROIC) | -44.18% |
| Return on Capital Employed (ROCE) | -34.74% |
| ROA (5Y Average) | -44.38% |
| ROIC (5Y Average) | -97.55% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 1.55x |
| Receivables Turnover | 6.40x |
| Cash Conversion Cycle | -480 days |
Scores
INSM has an Altman Z-Score of 7.39, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.39 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.52B over the last 12 months.
| Revenue | $1.52B |
|---|---|
| Revenue Growth (YoY) | +239.97% |
| Gross Profit | $1.28B |
| Operating Income | -$563.99M |
| Pretax Income | -$598.06M |
| Net Income | -$605.61M |
| EBITDA | -$533.41M |
| EBIT | -$566.02M |
| Reported EPS (TTM) | -$3.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 32.57% of the $2.23B in total assets.
| Cash and Equivalents | $396.56M |
|---|---|
| Total Debt | $555.09M |
| Net Debt | $158.53M |
| Net Debt Per Share | $0.72 |
| Working Capital | $1.11B |
| Shareholder Equity | $726.21M |
| Book Value Per Share | $3.32 |
| Tangible Book Value | $451.67M |
| Tangible Book Per Share | $2.06 |
| Total Assets | $2.23B |
| Total Liabilities | $1.50B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $31.95M of capital spending, operating cash flow left -$627.58M of free cash flow.
| Operating Cash Flow | -$595.62M |
|---|---|
| Capital Expenditures | $31.95M |
| Free Cash Flow | -$627.58M |
| FCF Per Share | -$2.87 |
| Depreciation and Amortization | $32.61M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -37.11%.
| Gross Margin | 84.40% |
|---|---|
| Operating Margin | -37.11% |
| Pretax Margin | -39.35% |
| Net Margin | -39.85% |
| EBITDA Margin | -35.10% |
| EBIT Margin | -37.24% |
| FCF Margin | -41.30% |
| Gross Margin (5Y Average) | 77.75% |
Growth
Revenue grew 35.20% a year over 3 years.
| Revenue Growth (3Y CAGR) | +35.20% |
|---|---|
| Revenue Growth (5Y CAGR) | +29.83% |
Dividends and Yields
INSM does not pay a dividend. Its free cash flow yield is -2.35%.
| FCF Yield | -2.35% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Mar 3, 2011.
| Last Split Date | Mar 3, 2011 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 10 similar companies, INSM has the 5th highest P/S.
P/S RatioPeer median 14.7x
ROICPeer median 4.83%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.48%
| P/S Ratio | 17.5x vs 14.7x median |
|---|---|
| ROIC | -44.18% vs 4.83% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +239.97% vs +13.48% median |
Analyst Forecast
Consensus estimates put revenue growth at 122.14% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +122.14% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About INSM
What is INSM's market cap?
Insmed has a market cap of $26.96B. Its enterprise value, which adds debt and subtracts cash, is $27.12B.
How many shares of INSM are outstanding?
Insmed has 218.79M shares outstanding. The count is up 3.32% from a year earlier.
Does INSM pay a dividend?
No. Insmed does not pay a dividend.
How much debt does INSM have?
Insmed has $555.09M of total debt and $396.56M of cash and equivalents, a net debt position of $158.53M.
INSM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts